
Joseph Joy
@josephjoy945706
DM Medical oncology resident CMC vellore
Jesus i believe in you
ID: 1674778530637570051
30-06-2023 13:56:23
28 Tweet
11 Takipçi
136 Takip Edilen

🔍 Key takeaways on Hereditary Breast Cancer Syndromes, from the new ⭐️ISMPO Guidelines on Breast Cancer in the Young.✨ 📄 Published in the latest Ind J Med Ped Oncology 🖊️ Lead: Dr. Jyoti Bajpai and team 👉 Read full article: ijmpo.org/ejournals/topi… #bcsm #breastcancer


HER2 Rx options in #LungCancer: Part 2/2 w/ Isabel Preeshagul & Eric K. Singhi, MD!! We 🗣️ the current & quickly changing treatment landscape in this space. Full📢 🌟 cor2ed.com/lung-connect/p… 🌟 oncbrothers.com/her2-nsclc-202… 🌟Also on “Oncology Brothers” Podcast #lcsm #OncTwitter #MedTwitter

A simple move, a big impact: Giving IV magnesium before cisplatin cut kidney injury risk by 20%! Safe. Cheap. Available. JAMA Oncology OncoAlert Oncology Brothers LARVOL jamanetwork.com/journals/jamao…




🚨 REMORA trial: Lenvatinib 💊 24mg OD showed 38% ORR 🚀 in advanced thymic carcinoma post-platinum chemo. SD in 57% ⚠️ Grade 3 HTN in 64% Promising 2nd-line option #ThymicCarcinoma #Lenvatinib The Lancet Oncology doi.org/10.1016/S1470-…




amazing collective effort from the group.. congratulations 🎊 research which matters and changes practice on the ground.. enough evidence to indicate that OMCT backbone with immunotherapy must be studied in a frontline trial.. The ASCO Post Dr Amol Akhade LARVOL Praveen Kumar Marimuthu Ajoy Oommen John

Nice slide to show PIK3, AKT and mTOR inhibitors for MBC ESMO - Eur. Oncology #esmobreast25



A detailed review of VEGF signaling and targeting, future directions. Open access that too. doi.org/10.1038/s41392… Dr Akhil Santhosh Dr. Foxpaws Fauxpas Animesh Valame MD DNB Josh Thomas Georgy Ajoy Oommen John Praveen Kumar Marimuthu





Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…



